Association of inherited variation in Toll-Like receptor genes with malignant melanoma susceptibility and survival

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Gast, Andreas ^a,c   Bermejo, Justo Lorenzo ^b   Claus, Rainer ^a   Brandt, Andreas ^a   Weires, Marianne ^a   Weber, Alexander ^a   Plass, Christoph ^a   Sucker, Antje ^c   Hemminki, Kari ^a   Schadendorf, Dirk ^c   Kumar, Rajiv ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GERMANY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TOLL LIKE RECEPTOR 2 GENE; TOLL LIKE RECEPTOR 3 GENE; TOLL LIKE RECEPTOR 4 GENE; TOLL LIKE RECEPTOR 5 GENE; TOLL LIKE RECEPTOR GENE; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; INHERITANCE; MIDDLE AGED; PATHOLOGY; SURVIVAL; TIME; TUMOR GENE;

TOLL LIKE RECEPTOR;

CASE-CONTROL STUDIES; FEMALE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GERMANY; HAPLOTYPES; HUMANS; INHERITANCE PATTERNS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; SURVIVAL ANALYSIS; TIME FACTORS; TOLL-LIKE RECEPTORS;

EID: 80052566598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024370     Document Type: Article

References (31)

1. Kalialis LV, Drzewiecki KT, Klyver H, (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19: 275-282.
2. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, et al. (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 1557-1563.
3. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-718.
4. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA, (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19: 3477-3482.
5. Akira S, Takeda K, Kaisho T, (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680.
6. Krieg AM, Vollmer J, (2007) Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220: 251-269.
7. Wang RF, Miyahara Y, Wang HY, (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27: 181-189.
8. Kumar H, Kawai T, Akira S, (2009) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388: 621-625.
9. Pasare C, Medzhitov R, (2005) Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 560: 11-18.
10. Misch EA, Hawn TR, (2008) Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) 114: 347-360.
11. Schwartz DA, Cook DN, (2005) Polymorphisms of the Toll-like receptors and human disease. Clin Infect Dis 41 (Suppl 7): S403-407.
12. El-Omar EM, Ng MT, Hold GL, (2008) Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 27: 244-252.
13. Marshak-Rothstein A, (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835.
14. Eigentler TK, Caroli UM, Radny P, Garbe C, (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759.
15. Agarwala SS, (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587-595.
16. Park BS, Song DH, Kim HM, Choi BS, Lee H, et al. (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
17. Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, et al. (2006) Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 177: 322-332.
18. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, et al. (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220: 47-59.
19. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, et al. (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29: 482-491.
20. Stark JR, Wiklund F, Gronberg H, Schumacher F, Sinnott JA, et al. (2009) Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 18: 1859-1863.
21. Abu-Maziad A, Schaa K, Bell EF, Dagle JM, Cooper M, et al. (2010) Role of Polymorphic Variants as Genetic Modulators of Infection in Neonatal Sepsis. Pediatr Res.
22. Bochud PY, Hawn TR, Siddiqui MR, Saunderson P, Britton S, et al. (2008) Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 197: 253-261.
23. Thuong NT, Hawn TR, Thwaites GE, Chau TT, Lan NT, et al. (2007) A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. Genes Immun 8: 422-428.
24. Nakamura J, Meguro A, Ota M, Nomura E, Nishide T, et al. (2009) Association of toll-like receptor 2 gene polymorphisms with normal tension glaucoma. Mol Vis 15: 2905-2910.
25. Kormann MS, Depner M, Hartl D, Klopp N, Illig T, et al. (2008) Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 122: 86-92, 92 e81-88.
26. Eder W, Klimecki W, Yu L, von Mutius E, Riedler J, et al. (2004) Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 113: 482-488.
27. Santin I, Bilbao JR, de Nanclares GP, Calvo B, Castano L, (2006) No association of TLR2 and TLR4 polymorphisms with type I diabetes mellitus in the Basque population. Ann N Y Acad Sci 1079: 268-272.
28. Malhotra D, Relhan V, Reddy BS, Bamezai R, (2005) TLR2 Arg677Trp polymorphism in leprosy: revisited. Hum Genet 116: 413-415.
29. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, et al. (2005) Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65: 11771-11778.
30. Cheng I, Plummer SJ, Casey G, Witte JS, (2007) Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16: 352-355.
31. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, et al. (2009) Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 69: 874-885.